Meliora Bio

Meliora Bio is a biotechnology company focused on redefining drug discovery through a mechanism-first approach. By leveraging machine learning and functional genomics, the company identifies the true mechanism of action for small molecule precision medicines in oncology. Meliora's platform aims to uncover why certain drugs are effective and use those insights to develop more potent and selective therapies for cancer patients. The company was founded on the insight that many drugs in clinical development do not actually operate through their purported molecular targets. Meliora uses CRISPR-based technology to map the genetic dependencies of drugs, ensuring that their pipeline candidates have validated targets and clear paths to clinical efficacy. Headquartered in New York, the company is backed by prominent investors including HOF Capital and the American Cancer Society's BrightEdge fund.